ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER

M. E. Uda¹, M. Rivano², V. Scintu², S. Cadelano¹, S. Colombo¹, S. G. Gheza¹, V. Garau¹, A. G. Carrucciu², P. Serra²
1. Graduate School in Hospital Pharmacy, University of Sassari, Sassari, Italy
2. Clinical Oncology Pharmacy Department, A. Businco Hospital, Cagliari, Italy
Abstract number: SPSQ-133 ATC code: L01 (Antineoplastic agents)

Background and importance
Nivolumab and atezolizumab are indicated in the treatment of the not small cells lung cancer (NSCLC) in patients who have previously received a chemotherapy treatment.

Aim and objectives
This analysis aims to report the clinical outcome in terms of Overall Survival (OS) and Progression Free Survival (PFS) in selected cohorts of patients.

Materials and methods
✓ Analysis conducted between 17/05/2018 - 24/05/2021.
✓ 29 Patients treated with nivolumab (240 mg q2w fixed-dose).
✓ 41 Patients treated with atezolizumab (1200 mg q3w fixed-dose).
✓ Clinical data, as the expression of Programmed Death Ligand 1 (PDL-1) and the performance status (ECOG-PS), were evaluated.
✓ Adverse drug reactions (ADRs) were observed through the National Pharmacovigilance Network.
✓ The OS and PFS analysis were made with R Software version 4.0.3.

Results
This investigation showed preliminary results in the 70 patients (of which 84% are male). The median OS was 14.4 months in nivolumab group. The median PFS was 5.1 months in atezolizumab group. ADRs occurred in the 24% of patients treated with nivolumab. Moreover, any ADRs occurred in the patients treated with atezolizumab.

Conclusions and relevance
This analysis shows, through real-life data, the effectiveness of nivolumab and atezolizumab. Concerning nivolumab, the results of median OS (14.4 months) and PFS (3.8 months) were similarly estimated as the Phase III CheckMate057 clinical trial (OS 12.2 months, PFS 2.3 months) [1]. Regarding atezolizumab, the results of median OS (7.2 months) and PFS (5.1 months) were similarly estimated as the Phase III OAK clinical trial (OS 13-8 months, PFS 2-8 months) [2].

References

Section 5: Patient safety and Quality Assurance
email: elisabetta.uda.meu@gmail.com